Aduro Says End Of Janssen Collaborations “Not A Lethal Blow”

Both Janssen and Aduro gradually realized the Listeria technology platform was not delivering hoped-for results. Aduro will not continue the projects abandoned by Janssen, and will focus on its STING and APRIL programs going forward.

Aduro BioTech Inc. quietly revealed in an Oct. 1 SEC filing that a pair of partnerships signed with Janssen Biotech Inc. in 2014 have ended, but management maintains the Johnson & Johnson affiliate’s decision was expected and not a lethal blow of any kind for its prospects going forward.

In an 8-K filing, Aduro reported that Janssen informed it on Sept. 25 that it was terminating a pair of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip